PL EN


Preferences help
enabled [disable] Abstract
Number of results
2019 | 73 | 283-292
Article title

Prognostic value of neurotrophic growth factor (BDNF) in patients with colorectal cancer during chemotherapy

Content
Title variants
PL
Wartość prognostyczna neurotropowego czynnika wzrostu (BDNF) u pacjentów z rakiem jelita grubego w trakcie chemioterapii
Languages of publication
EN EN
Abstracts
EN
INTRODUCTION: The brain-derived neurotrophic factor (BDNF) is a protein belonging to neurotrophins that plays a key role in the proper development and functioning of the mammalian central nervous system. Previous studies have focused on assessment of the BDNF concentration in blood serum as a potential biomarker in neurological disorders. Recently, the BDNF signalling pathway has been recognised as a potential target for anticancer drugs, while its receptor (TrkB) as an oncogene in colorectal cancer cells. Despite the significant role in carcinogenesis, there are few studies on BDNF as a biomarker in colorectal cancer. MATERIAL AND METHODS: The study included 25 patients with clinically and histopathologically confirmed colorectal cancer, who were qualified for treatment. Prior to the first administration of chemotherapy, venous blood samples were collected from the patients and the biochemical parameters routinely determined prior to treatment were evaluated. Additionally, the serum BDNF concentration was determined by the immunoenzymatic method in all the patients. RESULTS: The serum BDNF concentration in patients was 50.24 ± 23.37 ng/ml. The BDNF concentration did not differ significantly between women and men. A negative correlation was found between the BDNF and CRP concentration and the BDNF and LDH concentration. The BDNF levels were significantly higher in patients who underwent primary tumour resection before chemotherapy. There was no correlation between the BDNF concentration and age, gender, BMI, CEA marker and liver enzymes in patients with colorectal cancer. There was no correlation between the BDNF concentration and clinical response to the treatment. CONCLUSIONS: BDNF cannot be considered as a prognostic factor in patients with colorectal cancer.
PL
WSTĘP: Neurotropowy czynnik pochodzenia mózgowego (Brain-Derived Neutortophic Factor – BDNF) jest białkiem należącym do rodziny neurotrofin, które odgrywa kluczową rolę w prawidłowym rozwoju i funkcjonowaniu ośrodkowego układu nerwowego ssaków. Dotychczasowe badania dotyczyły głównie oceny stężenia BDNF w surowicy krwi, jako potencjalnego biomarkera w schorzeniach neurologicznych. Ostatnio ścieżka sygnałowa BDNF uznana została za potencjalne miejsce uchwytu leków przeciwnowotworowych, a jego receptor (TrkB) za onkogen w komórkach raka jelita grubego. Pomimo znaczącej roli w nowotworzeniu, niewiele jest prac dotyczących BDNF jako biomarkera w raku jelita grubego. MATERIAŁ I METODY: Badaniem objęto grupę 25 osób z potwierdzonym klinicznie i histopatologicznie rakiem jelita grubego, którzy zostali zakwalifikowani do leczenia. Przed pierwszorazowym podaniem chemioterapii od pacjentów pobrano próbki krwi żylnej i dokonano oceny parametrów biochemicznych oznaczanych rutynowo przed leczeniem. Dodatkowo metodą immunoenzymatyczną oznaczono stężenia BDNF w surowicy krwi wszystkich badanych pacjentów. WYNIKI: Stężenie BDNF w surowicy pacjentów wyniosło 50,24 ± 23,37 ng/ml i nie różniło się istotnie pomiędzy kobietami i mężczyznami. Stwierdzono ujemną korelację między stężeniem BDNF i CRP oraz BDNF i LDH. Stężenie BDNF było znamiennie wyższe u chorych, którzy przed chemioterapią byli poddani resekcji guza pierwotnego. Nie wykazano zależności pomiędzy stężeniem BDNF a wiekiem, płcią, wskaźnikiem BMI, markerem CEA oraz enzymami wskaźnikowymi wątroby u pacjentów z RJG. Nie zaobserwowano zależności pomiędzy stężeniem BDNF a odpowiedzią kliniczną na zastosowane leczenie. wnioski: BDNF nie może być uznany za czynnik prognostyczny u chorych z rakiem jelita grubego.
Discipline
Publisher

Year
Issue
73
Pages
283-292
Physical description
Contributors
  • Department of Toxicology and Health Protection, Faculty of Health Sciences in Bytom, Medical Uniwersity of Silesia in Katowice
  • Department of Toxicology and Health Protection, Faculty of Health Sciences in Bytom, Medical Uniwersity of Silesia in Katowice, aglogowska@sum.edu.pl
  • Oncological Ward, Independent Public Health Care Unit, Voivodeship Specialised Hospital No. 3, Rybnik, Poland
  • Department of Toxicology and Health Protection, Faculty of Health Sciences in Bytom, Medical Uniwersity of Silesia in Katowice
  • Wyższa Szkoła Biznesu w Dąbrowie Górniczej
  • Department of Pharmacology, Opole University, Opole, Poland
References
  • 1. Żełobowska K., Gumprecht J., Grzeszczak W. Neurotropowy czynnik pochodzenia mózgowego (BDNF) – udział w patogenezie insulinooporności i cukrzycy typu 2. Przew. Lek. 2007; 4: 79–83.
  • 2. Khan N., Smith M.T. Neurotrophins and Neuropatic Pain: Role in Pathobiology. Molecules 2015; 20(6): 10657–10688, doi: 10.3390/molecules200610657.
  • 3. Urbaniak A. Receptor p75NTR – rola w procesach wzrostu i śmierci komórki. Postepy Hig. Med. Dosw. 2012; 66: 304–310.
  • 4. Cunha C., Brambilla R., Thomas K.L. A simple role for BDNF in learning and memory? Front Mol. Neurosci. 2010; 3(1): 1–14, doi: 10.3389/neuro.02.001.2010. eCollection 2010.
  • 5. Brierley G., Priebe I, Purins L., Fung K., Tabor B., Lockett T., Nice E., Gibbs P., Tie J., McMurrick P., Moore J., Ruszkiewicz A., Burgess A., Cosgrove L.J. Serum concentrations of brain-derived neurotrophic factor (BDNF) are decreased in colorectal cancer patients. Cancer Biomark. 2013; 13(2): 67–73, doi: 10.3233/CBM-130345.
  • 6. Roesler R., de Farias C.B., Abujamra A.L., Brunetto A.L., Schwartsmann G. BDNF/TrkB signaling as anti-tumor target. Expert Rev. Anticancer Ther 2011; 11(10): 1473–1475, doi: 10.1586/era.11.150.
  • 7. Yang X., Martin T.A., Jiang W.G. Biological influence of brain‑derived neurotrophic factor (BDNF) on colon cancer cells. Exp. Ther. Med. 2013; 6(6): 1475–1481, doi: 10.3892/etm.2013.1330.
  • 8. Sarabi M., Perraud A., Mazouffre C., Nouaille M., Jauberteau MO., Mathonnet M. Psychoactive drugs influence brain-derived neurotrophic factor and neurotrophin 4/5 levels in the serum of colorectal cancer patients. Biomed. Rep. 2017; 6(1): 89–94, doi: 10.3892/br.2016.801.
  • 9. Akil H., Perraud A., Mélin C., Jauberteau M.O., Mathonnet M. Fine-tuning roles of endogenous brain-derived neurotrophic factor, TrkB and sortilin in colorectal cancer cell survival. PloS One 2011; 6(9): e25097, doi: 10.1371/journal.pone.0025097. Epub 2011 Sep 26.
  • 10. Lommatzsch M., Zingler D., Schuhbaeck K., Schloetcke K., Zingler C., Schuff-Werner P., Virchow J.C. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging 2005; 26(1): 115–123, doi: 10.1016/j.neurobiolaging.2004.03.002.
  • 11. Shimizu E., Hashimoto K., Okamura N., Koike K., Komatsu N., Kumakiri C., Nakazato M., Watanabe H., Shinoda N., Okada S., Iyo M. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol. Psychiatry 2003; 54(1): 70–75, doi: 10.1016/s0006-3223(03)00181-1.
  • 12. Karege F., Perret G., Bondolfi G., Schwald M., Bertschy G., Aubry J.M. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res. 2002; 109(2): 143–148, doi: 10.1016/s0165-1781(02)00005-7.
  • 13. Fujimura H., Altar CA., Chen R., Nakamura T., Nakahashi T., Kambayashi J., Sun B., Tandon N.N. Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb Haemost 2002; 87(4): 728–734.
  • 14. Toyooka K., Asama K., Watanabe Y., Muratake T., Takahashi M., Someya T., Nawa H. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res. 2002; 110(3): 249–257, doi: 10.1016/s0165-1781(02)00127-0.
  • 15. Noga O., Hanf G., Schäper C., O’Connor A., Kunkel G. The influence of inhalative corticosteroids on circulating Nerve Growth Factor, Brain-Derived Neurotrophic Factor and Neurotrophin-3 in allergic asthmatics. Clin. Exp. Allergy 2001; 31(12): 1906–1912, doi: 10.1046/j.1365-2222.2001.01249.x.
  • 16. Rosenfeld R.D., Zeni L., Haniu M., Talvenheimo J., Radka S.F., Bennett L., Miller J.A., Welcher A.A. Purification and identification of brain-derived neurotrophic factor from human serum. Protein Expr. Purif. 1995; 6(4): 465–471, doi: 10.1006/prep.1995.1062.
  • 17. Ziegenhorn A.A, Schulte-Herbrüggen O., Danker-Hopfe H., Malbranc M., Hartung H.D., Anders D., Lang U.E., Steinhagen-Thiessen E., Schaub R.T., Hellweg R. Serum neurotrophins—a study on the time course and influencing factors in a large old age sample. Neurobiol. Aging 2007; 28(9): 1436–1445, doi: 10.1016/j.neurobiolaging.2006.06.011.
  • 18. Bus B.A., Tendolkar I., Franke B., de Graaf J., den Heijer M., Buitelaar J.K., Oude Voshaar R.C. Serum brain-derived neurotrophic factor: determinants and relationship with depressive symptoms in a community population of middle-aged and elderly people. World J. Biol. Psychiatry 2012; 13(1): 39–47, doi: 10.3109/15622975.2010.545187.
  • 19. Scharfman H.E., MacLusky N.J. Estrogen and brain-derived neurotrophic factor (BDNF) in hippocampus: complexity of steroid hormone-growth factor interactions in the adult CNS. Front Neuroendocrinol 2006; 27(4): 415–435, doi: 10.1016/j.yfrne.2006.09.004.
  • 20. Pillai A., Bruno D., Sarreal A.S., Hernando R.T., Saint-Louis L.A., Nierenberg J., Ginsberg S.D., Pomara N., Mehta P.D., Zetterberg H., Blennow K., Buckley P.F. Plasma BDNF levels vary in relation to body weight in females. PLoS One 2012; 7(7): e39358, doi: 10.1371/journal.pone.0039358.
  • 21. Lang U.E., Hellweg R., Gallinat J. BDNF serum concentrations in healthy volunteers are associated with depression-related personality traits. Neuropsychopharmacology 2004; 29(4): 795–798, doi: 10.1038/sj.npp.1300382.
  • 22. Laske C., Stransky E., Eschweiler G.W., Klein R., Wittorf A., Leyhe T., Richartz E., Köhler N., Bartels M., Buchkremer G., Schott K. Increased BDNF serum concentration in fibromyalgia with or without depression or antidepressants. J. Psychiatr. Res. 2007; 41(7): 600–605, doi: 10.1016/j.jpsychires.2006.02.007.
  • 23. Shimizu E., Hashimoto K., Okamura N., Koike K., Komatsu N., Kumakiri C., Nakazato M., Watanabe H., Shinoda N., Okada S., Iyo M. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol. Psychiatry 2003; 54(1): 70–75, doi: 10.1016/s0006-3223(03)00181-1.
  • 24. Tanaka K., Okugawa Y., Toiyama Y., Inoue Y., Saigusa S., Kawamura M., Araki T., Uchida K., Mohri Y., Kusunoki M. Brain-derived neurotrophic factor (BDNF)-induced tropomyosin-related kinase B (Trk B) signaling is a potential therapeutic target for peritoneal carcinomatosis arising from colorectal cancer. PLoS One 2014; 9(5): e96410, doi: 10.1371/journal.pone.0096410.
  • 25. Brunetto de Farias C., Rosemberg D.B., Heinen T.E., Koehler-Santos P., Abujamra A.L., Kapczinski F., Brunetto A.L., Ashton-Prolla P., Meurer L., Reis Bogo M., Damin D.C., Schwartsmann G., Roesler R. BDNF/TrkB content and interaction with gastrin-releasing peptide receptor blockade in colorectal cancer. Oncology 2010; 79(5-6): 430–439, doi: 10.1159/000326564.
  • 26. Yang Z.F., Ho D.W., Lau C.K., Tam K.H., Lam C.T., Yu W.C., Poon R.T., Fan S.T. Significance of the serum brain-derived neurotrophic factor and platelets in hepatocellular carcinoma. Oncol. Rep. 2006; 16(6): 1237–1243.
  • 27. Rosas-Vargas H., Martinez-Ezquerro J.D., Bienvenu T. Brain-derived neurotrophic factor, food intake regulation, and obesity. Arch. Med. Res. 2011; 42(6): 482–494, doi: 10.1016/j.arcmed.2011.09.005.
  • 28. Gunstad J., Schofield P., Paul R.H., Spitznagel M.B., Cohen R.A., Williams L.M., Kohn M., Gordon E. BDNF Val66Met polymorphism is associated with body mass index in healthy adults. Neuropsychobiology 2006; 53(3): 153–156, doi: 10.1159/000093341.
  • 29. El-Gharbawy A.H., Adler-Wailes D.C., Mirch M.C., Theim K.R., Ranzenhofer L., Tanofsky-Kraff M., Yanovski J.A. Serum brain-derived neurotrophic factor concentrations in lean and overweight children and adolescents. J. Clin. Endocrinol. Metab. 2006; 91(9): 3548–3552, doi: 10.1210/jc.2006-0658.
  • 30. Stanek K., Gunstad J., Leahey T., Glickman E., Alexander T., Spitznagel M.B., Juvancic Heltzel J., Murray L. Serum brain-derived neurotrophic factor is associated with reduced appetite in healthy older adults. J. Nutr. Health Aging 2008; 12(3): 183–185, doi: 10.1007/bf02982616.
  • 31. Nakazato M., Hashimoto K., Shimizu E., Kumakiri C., Koizumi H., Okamura N., Mitsumori M., Komatsu N., Iyo M. Decreased levels of serum brain-derived neurotrophic factor in female patients with eating disorders. Biol. Psychiatry 2003; 54(4): 485–490, doi: 10.1016/s0006-3223(02)01746-8.
  • 32. Patani N., Jiang WG., Mokbel K. Brain-derived neurotrophic factor expression predicts adverse pathological & clinical outcomes in human breast cancer. Cancer Cell. Int. 2011; 11(1): 23, doi: 10.1186/1475-2867-11-23.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-d1ebfeef-a553-47c9-ad46-d9712deb73aa
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.